| | Parameters | Successive bilateral SSNHL () | Unilateral SSNHL () |
| | Age (years), | | | | , number | 9 : 24 | 114 : 101 | | Males : females, number | 18 : 15 | 112 : 103 | | NLR, | | | | , number | 4 : 29 | 111 : 104 | | MLR, | | | | , number | 14 : 19 | 167 : 48 | | PLR, | | | | , number | 12 : 21 | 148 : 67 | | LDL (mmol/L), | | | | , number | 9 : 24 | 146 : 69 | | HDL (mmol/L), | | | | , number | 23 : 10 | 77 : 138 | | Total cholesterol (mmol/L), | | | | Triglyceride (mmol/L), | | | | Fibrinogen (g/L), | | | | , number | 18 : 15 | 170 : 45 | | PT (sec), | | | | APTT (sec), | | | | Smoking, number (%) | 12 (36%) | 66 (31%) | | Alcohol consumption, number (%) | 5 (15%) | 38 (18%) | | Hypertension, number (%) | 8 (24%) | 42 (20%) | | Diabetes, number (%) | 19 (57%) | 67 (32%) | | Statins, number (%) | 8 (24%) | 45 (21%) | | Antihypertensive therapy, number (%) | 7 (21%) | 40 (19%) | | Nitrates | 0 (0%) | 0 (0%) | | Angiotensin-converting enzyme inhibitors | 2 (6%) | 10 (5%) | | Beta blockers | 1 (3%) | 5 (2%) | | Angiotensin receptor blockers | 2 (6%) | 10 (5%) | | Calcium channel blockers | 2 (6%) | 15 (7%) | | Accompanying symptoms, number (%) | | | | Dizziness | 12 (36%) | 71 (33%) | | Tinnitus | 23 (70%) | 146 (68%) | | Ear fullness | 18 (55%) | 112 (52%) | | Total effective rate, number (%) | 4 (12%) | 126 (59%) |
|
|
